Interviewer: Professor Markman,
thank you for sparing the time today,
we're going to be discussing
the current status and
future direction of
precision cancer medicine.
First of all,
let me let you set out your stall.
What is the current state and
what are the future directions?
Prof. Markman: I think the one
of the most important aspects of
this topic is a definition
of what we mean, or
to be clearer since I am
speaking what I mean,
when I use the term
'precision cancer medicine'.
I am referring to a basic
process (I've used
this term in in my writing), not an event.
We will not at some point declare,
that we're now in the era of
precision cancer medicine because
a particular trial has shown that
using a molecular target with a drug
has been effective and that means
precision cancer medicine is here.
That's an event, that's the end
of a trial, it's an outcome.
That is not what precision cancer
medicine is to me, what precision
cancer medicine is to me (and is I believe
a correct definition) is an approach,
both in terms of what we're doing
now in our clinical research,
but increasingly importantly
in the standard of care for